The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen.
Do-Youn Oh
No relevant relationships to disclose
Keun-Wook Lee
No relevant relationships to disclose
Jae Yong Cho
No relevant relationships to disclose
Won Ki Kang
No relevant relationships to disclose
Sun Young Rha
No relevant relationships to disclose
Yung-Jue Bang
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer